-PTI Study claims more than half of them died in the first 28 days of their life More than 16.8 lakh children under five years died of infectious, but preventable, diseases in India in 2010 and more than half of them could not complete the first month of their life, a new study has claimed. Of the total deaths, 52 per cent, or about 0.875 million, were among the children who died in...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

-CNN-IBN More than 3000 working poor are right now agitating at Jantar Mantar, New Delhi, under the banner of Pension Parishad as the curtains are up on the 'right to pension' campaign. Spearheaded by Aruna Roy, the Mazdoor Kisan Shakti Sangathan leader and member of the National Advisory Council (NAC), the campaign seeks universalisation of a minimum pension of Rs 2000 per person per month for all elderly citizens of...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

A report by a parliamentary committee has shown that the drug industry regulator, the Drug Controller General of India (DCGI), has been approving, on average, one new drug a month without conducting mandatory clinical trials or seeking expert medical opinion—findings that expose the deep flaws prevalent in India’s drug approval process. The committee has asked the health ministry to withdraw the discretionary powers given to the Central Drugs Standard Control Organization...